The stock of Stemline Therapeutics Inc (NASDAQ:STML) is a huge mover today! About 376,255 shares traded hands or 122.01% up from the average. Stemline Therapeutics Inc (NASDAQ:STML) has risen 92.43% since March 4, 2016 and is uptrending. It has outperformed by 84.39% the S&P500.
The move comes after 5 months positive chart setup for the $236.17M company. It was reported on Oct, 7 by Barchart.com. We have $29.32 PT which if reached, will make NASDAQ:STML worth $316.47M more.
Analysts await Stemline Therapeutics Inc (NASDAQ:STML) to report earnings on November, 4. They expect $-0.55 EPS, down 3.77% or $0.02 from last year’s $-0.53 per share. After $-0.52 actual EPS reported by Stemline Therapeutics Inc for the previous quarter, Wall Street now forecasts 5.77% negative EPS growth.
According to Zacks Investment Research, “Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York.”
Insitutional Activity: The institutional sentiment increased to 1.08 in 2016 Q2. Its up 0.12, from 0.96 in 2016Q1. The ratio is positive, as 9 funds sold all Stemline Therapeutics Inc shares owned while 15 reduced positions. 8 funds bought stakes while 18 increased positions. They now own 9.63 million shares or 1.71% less from 9.80 million shares in 2016Q1.
Int Grp Inc Inc has 0% invested in the company for 9,705 shares. Franklin Resources has 2.10 million shares for 0.01% of their US portfolio. Wells Fargo Com Mn, a California-based fund reported 7,834 shares. Bailard last reported 0.08% of its portfolio in the stock. Invesco Limited has invested 0% of its portfolio in Stemline Therapeutics Inc (NASDAQ:STML). Moreover, Nationwide Fund Advsrs has 0% invested in Stemline Therapeutics Inc (NASDAQ:STML) for 22,395 shares. Credit Suisse Ag accumulated 10,567 shares or 0% of the stock. Jacobs Levy Equity Management has 55,854 shares for 0.01% of their US portfolio. Northern last reported 0% of its portfolio in the stock. Timessquare Cap Mngmt Ltd Liability Com has 950,005 shares for 0.04% of their US portfolio. Bnp Paribas Arbitrage Sa holds 0% or 652 shares in its portfolio. California State Teachers Retirement Sys has 35,349 shares for 0% of their US portfolio. Geode Cap Mngmt Ltd Liability Co has invested 0% of its portfolio in Stemline Therapeutics Inc (NASDAQ:STML). Morgan Stanley has 222 shares for 0% of their US portfolio. Baker Bros Ltd Partnership accumulated 333,497 shares or 0.02% of the stock.
Another recent and important Stemline Therapeutics Inc (NASDAQ:STML) news was published by Marketwatch.com which published an article titled: “- Edgar Online – (EDG = 10Q, 10K)” on August 22, 2012.
STML Company Profile
Stemline Therapeutics, Inc., incorporated on August 8, 2003, is a clinical-stage biopharmaceutical firm focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Firm is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.